Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Learn more about:
Related Clinical Trial
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Official Title

A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy

Brief Summary

      -  Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based
           chemotherapy

        -  Trial Type : Single arm, prospective trial

        -  Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib)

        -  Treatment Groups : Single arm

        -  Number of trial participants : 30
    

Detailed Description

      1. Timing of Dose Administration for Pembrolizumab Trial interventions should be
           administered on Day 1 of each cycle after all procedures/assessments have been completed
           as detailed on the Schedule. Trial interventions may be administered up to 3 days before
           or after the scheduled Day 1 of each cycle due to administrative reasons.

           All trial interventions will be administered on an outpatient basis. Pembrolizumab 200
           mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make
           every effort to target infusion timing to be as close to 30 minutes as possible.
           However, given the variability of infusion pumps from site to site, a window of -5
           minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10
           min).

        2. Lenvatinib administration Lenvatinib will be administered with water orally once a day
           (with or without food) in 21-day cycles at approximately the same time each day.
           Treatment cycles will be counted continuously regardless of dose interruptions. On Day 1
           (D1) of each cycle, it will be administered approximately 1 hour after completion of
           pembrolizumab administration.

        3. Treatment Period The Treatment Phase will begin with the administration of the first
           dose of study treatment to the first subject in Cycle 1 and continues in 21-day (3-week)
           cycles. Subjects will continue to receive study treatment until confirmed PD by IIR,
           development of unacceptable toxicity, subject request, withdrawal of consent, completion
           of 35 treatments (approximately 2 years) with pembrolizumab, or study termination by the
           sponsor. Those subjects that discontinue study treatment transition to the Off-Tx Visit
           of the Follow-up Period.

        4. Safety Follow-Up Visit The mandatory Safety Follow-Up Visit should be conducted
           approximately 30 days after the last dose of study intervention or before the initiation
           of a new anti-cancer treatment, whichever comes first.

        5. Efficacy Follow-up Visits Participants who complete the protocol-required cycles of
           study intervention of who discontinue study intervention for a reason other than disease
           progression will begin the Efficacy Follow-Up Phase and should be assessed every 6 weeks
           (42 ± 7 days) by radiologic imaging to monitor disease status. After 6 months, the
           imaging time point will occur every 9 weeks (± 7 days). Every effort should be made to
           collect information regarding disease status until the start of new anti-cancer therapy,
           disease progression, death, end of the study. Information regarding post-study
           anti-cancer treatment will be collected if new treatment is initiated. Participants who
           completed all efficacy assessments and/or will not have further efficacy assessments
           must enter the Survival Follow-up Phase.

        6. Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event
           Information :

      All AEs, SAEs, and other reportable safety events that occur after the consent form is signed
      but before intervention allocation must be reported by the investigator if the event cause
      the participant to be excluded from the study, or is the result of a protocol-specified
      intervention, including but not limited to washout or discontinuation of usual therapy, diet,
      or a procedure.

        -  All AEs from the time of intervention allocation through 30 days following cessation of
           study intervention must be reported by the investigator.

        -  All AEs meeting serious criteria, from the time of intervention allocation through 90
           days following cessation of study intervention or 30 days following cessation of study
           intervention if the participant initiates new anticancer therapy, whichever is earlier,
           must be reported by the investigator.

        -  All pregnancies and exposure during breastfeeding, from the time of intervention
           allocation through 120 days following cessation of study intervention, or 30 days
           following cessation of study intervention if the participant initiates new anticancer
           therapy must be reported by the investigator.

        -  Additionally, any SAE brought to the attention of an investigator at any time outside of
           the time period specified above must be reported immediately to MSD if the event is
           considered drug-related.

      Investigators are not obligated to actively seek AEs or SAEs or other reportable safety
      events in former study participants. However, if the investigator learns of any SAE,
      including a death, at any time after a participant has been discharged from the study, and
      he/she considers the event to be reasonably related to the study intervention or study
      participation, the investigator must promptly notify MSD.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

To assess the antitumor activity of pembrolizumab plus lenvatinib in patients with advanced ACC.


Condition

Adrenocortical Carcinoma

Intervention

Pembrolizumab / Lenvatinib

Study Arms / Comparison Groups

 Treatment arm
Description:  Pembrolizumab 200mg q 3wks IV / Lenvatinib 20mg daily once PO q 3wks

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

November 1, 2021

Completion Date

August 31, 2026

Primary Completion Date

August 31, 2025

Eligibility Criteria

        Inclusion Criteria:

          1. Male/female participants who are at least 19 years of age on the day of signing
             informed consent with histologically confirmed diagnosis of adrenal cortical carcinoma
             will be enrolled in this study.

          2. Patients with locally advanced, recurrent, or metastatic disease not amenable to
             surgery, radiotherapy, or combined modality therapy with curative intent.

          3. Patients who have received prior systemic therapy including combined mitotane and
             cisplatin-based chemotherapy as a palliative aim systemic therapy in advanced setting,
             and have had disease progression within 6 months of the last dose of the most recent
             systemic therapy. Patients who discontinued prior therapy due to intolerable
             toxicities can be included.

          4. Patients who have refused cytotoxic chemotherapy can be included.

          5. Patients should have measurable disease according to RECIST v1.1 meeting the following
             criteria:

               1. at least 1 lesion of ≥10 mm in the longest diameter for a non-lymph node or ≥15
                  mm in the short-axis diameter for a lymph node that is serially measurable
                  according to RECIST using CT or MRI

               2. lesions that have had external beam radiotherapy or other loco-regoinal therapies
                  such as radiofrequency ablastion must show subsequent evidence of substantial
                  size increase to be deemed a target lesion.

          6. Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS)
             0 to 1

          7. Adequately controlled blood pressure (BP) with or without antihypertensive
             medications, defined as BP≤150/90 mmHg at screening and no change in hypertensive
             medications within 1 week prior to the cycle 1 day 1.

          8. Adequate renal function defined as creatinine ≤1.5 times the upper limit of normal
             (×ULN) or calculated creatinine clearance ≥30 ml/min per the Cockcroft and Gault
             formula

          9. Adequate bone marrow function:

               1. Absolute neutrophil count (ANC)≥1500/mm3 (≥1.5×103/μL)

               2. platelets≥100,000/ mm3 (≥100×109/L)

               3. hemoglobin≥9.0 g/dL

         10. adequate blood coagulation function defined by international Normlized Ratio (INR)≤1.5
             unless participant is receiving anticoagulation therapy

         11. adequate liver function defined by:

               1. total bilirubin ≤1.5×ULN except for unconjugated hyperbilirubinemia of Gilbert's
                  syndrome

               2. alkaline phosphatase (ALP), alanine aminotransferase (ALT), and asparate
                  aminotransferase (AST)≤3×ULN (in the case of liver metastases ≤5×ULN), unless
                  there are bone metastases. Subject with ALP values >3×ULN and known to have bone
                  metastases can be included.

         12. Life expectancy more than 3 months

         13. Patients should agree to discontinue mitotane

         14. Females of childbearing potential must agree to use a highly effective method of
             contraception for the entire study period and for 120 days after study discontinuation
             (see appendix 7)

         15. Male participants who are partners of women of childbearing potential must use a
             condom plus spermicide and their female partners if of childbearing potential must use
             a highly effective method of contraception (see inclusion criterion #14 and appendix
             7) beginning at least 1 mentrual cycle prior to starting study drugs, throughout the
             entire study period, and for 120 days after the last dose of study drug, unless the
             male subjects are totally sexually abstinent or have undergone a successful vasectomy
             with confirmed azoospermia or unless the female partners have been sterilized
             surgically or are otherwise proven sterile.

         16. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy
             of a tumor lesion not previously irradiated for biomarker analysis. Formalin-fixed,
             paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained
             biopsies are preferred to archived tissue. In the case of archival tissue cannot be
             provided, patients with inaccessible tumors for biopsy specimens or patients who
             refuse to be biopsied can be enrolled without a biopsy at the discretion of treating
             physician.

         17. Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol.

        Exclusion Criteria:

          1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,
             OX 40, CD137).

          2. Has received prior therapy with any VEGFR TKI or monoclonal antibody targeting VEGF
             pathway.

          3. Has received major surgery within 2 weeks of start of study intervention. Participants
             must have recovered from any toxicity and/or complications from major surgery prior to
             starting therapy.

          4. Previous radiotherapy to the only measurable lesion: but previous radiotherapy will be
             permitted unless the lesion is the only measurable lesion.

          5. Subjects having >1+ proteinuria on urinalysis will undergo 24-hour urine collection
             for quantitative assessment of proteinuria. Subjects with urine protein ≥1g/24-hour
             will be ineligible.

          6. Gastrointestinal malabsorption, gastrointestinal obstruction, or any other condition
             that might affect the absorption of lenvatinib.

          7. Significant cardiovascular impairment within 6 months of the first dose of study drug.
             History of congestive heart failure greater than New York Heart Association (NYHA)
             Class II, unstable angina, myocardial infarction or stroke, cardiac arrhythmia
             associated with significant cardiovascular impairment, or a left ventricular ejection
             fracture (LVEF) below the institutional normal range as determined by MUGA or
             echocardiogram.

          8. Prolongation of QTc interval to >480 msec

          9. Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree
             of tumor invasion/infiltration of major blood vessels should be considered because of
             the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis
             following lenvatinib therapy.

         10. Has received a live vaccine within 30 days prior to the first dose of study drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

         11. Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study intervention.

         12. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug. The use
             of physiologic doses of corticosteroids may be approved at the discretion of treating
             physician. In mitotane treated subject, adrenal insufficiency happens inevitably and
             required dose of corticosteroid is higher than usual due to altered metabolism of
             corticosteroid.48 Therefore, the decision on whether the dose of maintenance
             corticosteroid is acceptable for enrollment depends on investigator.

         13. Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years. Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical
             cancer in situ) that have undergone potentially curative therapy are not excluded.
             Clinically insignificant or curatively treated localized prostate cancer and
             curatively treated thyroid cancer of any stage can be included at the discretion of
             treating physician.

         14. Has known active CNS metastases and/or carcinomatous meningitis. Participants with
             previously treated brain metastases may participate provided they are radiologically
             stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging
             (note that the repeat imaging should be performed during study screening), clinically
             stable and without requirement of steroid treatment for at least 14 days prior to
             first dose of study intervention.

         15. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment and is allowed.

         16. Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis. Non-infectious pneumonitis include, but not limited to, idiopathic
             pulmonary fibrosis, organizing pneumonia, or drug-induced pneumonitis. History of
             radiation pneumonitis in the radiation field is permitted.

         17. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is
             detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required
             unless mandated by local health authority.

         18. Has an active tuberculosis. However, inactive tuberculosis (previously treated or
             latent infection without evidence of active disease) is allowed.

         19. Has a known history of Human Immunodeficiency Virus (HIV) infection.

         20. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the participant's
             participation for the full duration of the study, or is not in the best interest of
             the participant to participate, in the opinion of the treating investigator.

         21. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         22. All females with child-bearing capacity who has a positive urine pregnancy test within
             72 hours prior to the first dose of study drug. If the urine test is positive or
             cannot be confirmed as negative, a serum pregnancy test will be required.

         23. Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of trial treatment.

         24. Has had an allogenic tissue/solid organ transplant.

         25. Serious nonhealing wound, ulcer, or bone fracture.
      

Gender

All

Ages

19 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Tak Yun, +82-31-920-0950, [email protected]



Administrative Informations


NCT ID

NCT05036434

Organization ID

MCT-STRC-02


Responsible Party

Principal Investigator

Study Sponsor

National Cancer Center, Korea


Study Sponsor

Tak Yun, Principal Investigator, National Cancer Center, Korea


Verification Date

August 2021